Liraglutide for treating type 1 diabetes

Expert Opinion on Biological Therapy

Volumn 16, Issue 4, 2016, Pages 579-590

  Dejgaard, Thomas Fremming ^a,b   Frandsen, Christian Seerup ^a   Holst, Jens Juul ^a,c   Madsbad, Sten ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Body weight; GLP 1 receptor agonist; Glucagon like peptide 1; HbA1c; Hypoglycaemia; Liraglutide; Type 1 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; INCRETIN;

ADD ON THERAPY; CONSTIPATION; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART RATE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NAUSEA; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING; AGONISTS; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; LIRAGLUTIDE;

EID: 84962199732     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1160050     Document Type: Review

References (26)

1. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965 Oct;14(10):619-633.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-986. doi:10. 1056/NEJM199309303291401.
3. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014 Jan;37(Suppl 1):S14-S80. doi:10. 2337/dc14-S014.
4. Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in Type 1 diabetes. Diabet Med. 2010 Apr;27 (4):398-404. doi:10. 1111/j. 1464-5491. 2010. 02956. x.
5. Chillaron JJ, Flores Le-Roux JA, Benaiges D, et al. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014 Feb;63(2):181-187. doi:10. 1016/j. metabol. 2013. 10. 002.
6. Metascreen Writing C, Bonadonna R, Cucinotta D, et al. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care. 2006 Dec;29(12):2701-2707. doi:10. 2337/dc06-0942.
7. Thorn LM, Forsblom C, Fagerudd J, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005 Aug;28 (8):2019-2024.
8. Lee Y, Wang M-Y, Du XQ, et al. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes. 2011 Feb;60(2):391-397. doi:10. 2337/db10-0426.
9. Holst JJ. Incretin hormones and the satiation signal. Int J Obes. 2013 Sep;37(9):1161-1168. doi:10. 1038/ijo. 2012. 208.
10. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009 Dec;11(12):1163-1172. doi:10. 1111/j. 1463-1326. 2009. 01158. x.
11. Kjems LL, Holst JJ, Volund A, et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003 Feb;52(2):380-386.
12. Lind M, Hirsch IB, Tuomilehto J, et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). BMJ. 2015;351:h5364.
13. Harrison LB, Mora PF, Clark GO, et al. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Invest Med. 2013 Jan;61 (1):40-44. doi:10. 231/JIM. 0b013e318279b7d6.
14. Kielgast U, Krarup T, Holst JJ, et al. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care. 2011 Jul;34(7):1463-1468.
15. Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract. 2013 Nov;19(6):963-967. doi:10. 4158/EP13065. OR.
16. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011 Jul;165(1):77-84. doi:10. 1530/EJE-11-0330.
17. Crisci I, Aragona M, Politi KS, et al. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetol. 2015 Dec;52 (6):1129-1133. doi:10. 1007/s00592-015-0800-6.
18. Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016 Mar;4(3):221-232.
19. Frandsen CS, Dejgaard TF, Holst JJ, et al. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study. Diabetes Care. 2015 Dec;38 (12):2250-2257.
20. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-1439. doi:10. 1152/physrev. 00034. 2006.
21. Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 2006 Mar;290(3):E550-E559. doi:10. 1152/ajpendo. 00484. 2005.
22. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008 Mar;57(3):678-687. doi:10. 2337/db07-1124.
23. Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003 Jan;88(1):220-224. doi:10. 1210/jc. 2002-021053.
24. Gutniak M, Orskov C, Holst JJ, et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992 May 14;326 (20):1316-1322.
25. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. 2006 Feb;49(2):253-260.
26. Thorens B, Porret A, Buhler L, et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes. 1993 Nov;42(11):1678-1682.